Stanley J. Marciniak

Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis

Howard Sofen, Stacy Smith, Robert Matheson et al. · Journal of Allergy and Clinical Immunology · 2014 · 302 citations · Full text

Life Sciences, Dermatology, Immunology +17

Pharmacokinetics and Safety of Golimumab, a Fully Human Anti‐TNF‐α Monoclonal Antibody, in Subjects With Rheumatoid Arthritis

Honghui Zhou, Haishan Jang, Roy Fleischmann et al. · The Journal of Clinical Pharmacology · 2007 · 194 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

An Additional Mechanism of Action of Abciximab: Dispersal of Newly Formed Platelet Aggregates

Stanley J. Marciniak, Mark Furman, Alan D. Michelson et al. · Thrombosis and Haemostasis · 2002 · 89 citations

Medicine, Hematology, Pharmacology +17

First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis

Yanli Zhuang, César A. Calderón, Stanley J. Marciniak et al. · European Journal of Clinical Pharmacology · 2016 · 83 citations

Pharmacy, Immunology, Pharmacokinetics +13

Evaluation of disease‐mediated therapeutic protein–drug interactions between an anti–interleukin‐6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach

Yanli Zhuang, Dick E. de Vries, Zhenhua Xu et al. · The Journal of Clinical Pharmacology · 2015 · 80 citations

Medicine, Pharmacokinetics, Pharmacology +17